We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $767M
1-Year Est. Return 119.71%
This Fund
S&P 500
This Quarter Est. Return
-2.89%
1 Year Est. Return
+119.71%
3 Year Est. Return
+244.81%
5 Year Est. Return
+382.5%
10 Year Est. Return
+2,655.81%
AUM
$935M
AUM Growth
+$227M
Cap. Flow
-$29.6M
Cap. Flow %
-3.17%
Top 10 Hldgs %
70.78%
Holding
86
New
20
Increased
18
Reduced
12
Closed
29

Top Buys

Rank Stock Value
1
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$32.9M
2
LLY icon
Eli Lilly
LLY
+$18.6M
3
FIVN icon
FIVE9
FIVN
+$11.3M
4
NICE icon
Nice
NICE
+$11.2M
5
META icon
Meta Platforms (Facebook)
META
+$9.65M

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$26.7M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$16.3M
3
KYMR icon
Kymera Therapeutics
KYMR
+$15.6M
4
ZIM icon
ZIM Integrated Shipping Services
ZIM
+$10.8M
5
GNRC icon
Generac Holdings
GNRC
+$9.81M

Sector Composition

Rank Sector Weight
1 Miscellaneous 47.92%
2 Healthcare 47.59%
3 Technology 3.05%
4 Communication Services 0.86%
5 Financials 0.27%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OTMO
51
DELISTED
Otonomo Technologies Ltd. Ordinary shares
OTMO
$431K 0.05%
26,124
– –
ARBE icon
52
Arbe Robotics
ARBE
$86.4M
$237K 0.03%
43,165
– –
IMTXW
53
DELISTED
Immatics N.V. Warrants
IMTXW
$204K 0.02%
100,000
– –
VINC
54
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$93K 0.01%
3,523
-32,485
-90% -$1.44M
ABNB icon
55
CALL
Airbnb
ABNB
$97.7B
– –
-24,300
Closed -$4.17M
ALNY icon
56
Alnylam Pharmaceuticals
ALNY
$32.5B
– –
-24,768
Closed -$3.51M
ASND icon
57
Ascendis Pharma A/S
ASND
$15.8B
– –
-26,529
Closed -$3.11M
BMRN icon
58
BioMarin Pharmaceuticals
BMRN
$12.6B
– –
-211,326
Closed -$16.3M
CAT icon
59
Caterpillar
CAT
$366B
– –
-12,000
Closed -$2.67M
CSTE icon
60
Caesarstone
CSTE
$97.2M
– –
-428,046
Closed -$4.5M
BGMS
61
Bio Green Med Solution Inc
BGMS
$6.11M
– –
-141
Closed -$1.55M
FATE icon
62
Fate Therapeutics
FATE
$303M
– –
-89,425
Closed -$3.47M
FIVN icon
63
CALL
FIVE9
FIVN
$2.54B
– –
-248,900
Closed -$27.5M
IMUX icon
64
Immunic
IMUX
$140M
– –
-58,321
Closed -$6.59M
KRYS icon
65
Krystal Biotech
KRYS
$9.98B
– –
-25,310
Closed -$1.68M
KYMR icon
66
Kymera Therapeutics
KYMR
$9.88B
– –
-368,061
Closed -$15.6M
MA icon
67
Mastercard
MA
$497B
– –
-12,100
Closed -$4.32M
NAUT icon
68
Nautilus Biotechnolgy
NAUT
$124M
– –
-840,000
Closed -$3.65M
TEAD
69
Teads Holding Co
TEAD
$49.5M
– –
-52,531
Closed -$564K
PERI icon
70
Perion Network
PERI
$345M
– –
-306,051
Closed -$6.88M
PFE icon
71
Pfizer
PFE
$158B
– –
-515,070
Closed -$26.7M
QQQ icon
72
PUT
Invesco QQQ Trust
QQQ
$482B
– –
-126,000
Closed -$45.7M
REPL icon
73
Replimune Group
REPL
$1.2B
– –
-212,640
Closed -$3.61M
RUN icon
74
CALL
Sunrun
RUN
$2.14B
– –
-228,000
Closed -$6.92M
RUN icon
75
Sunrun
RUN
$2.14B
– –
-150,000
Closed -$4.56M
1 2
3
4

Similar funds

ISWM
Independent Solutions Wealth Management Williamsville, New York $766M AUM 31.53% 1-Year Est. Return
ACP
Albar Capital Partners London, United Kingdom $767M AUM 61.96% 1-Year Est. Return
NIM
Nexus Investment Management Toronto, Ontario, Canada $767M AUM 30.97% 1-Year Est. Return
ACM
Arvin Capital Management Austin, Texas $766M AUM 36.51% 1-Year Est. Return
CBT
Crews Bank & Trust Wauchula, Florida $766M AUM 19.5% 1-Year Est. Return
SPIA
Strategic Point Investment Advisors Providence, Rhode Island $767M AUM 17.58% 1-Year Est. Return
CNB
Camden National Bank Camden, Maine $767M AUM 14.32% 1-Year Est. Return
HI
Hendershot Investments Centreville, Virginia $766M AUM 10.81% 1-Year Est. Return

Sphera Funds Management's Q2 2022 Portfolio in Review

As of Q2 2022, Sphera Funds Management held 86 positions worth $935M, up 32% from $708M the previous quarter. Its ten largest holdings account for 71% of the portfolio.

Sphera Funds Management withdrew a net $29.6M in Q2 2022, closing 29 positions and reducing 12 holdings. Its most notable exit was Pfizer, an estimated $26.7M position sold in full.

By sector, the portfolio is most concentrated in Miscellaneous at 48% of assets, up from 16% a quarter earlier, followed by Healthcare and Technology.

Against the trend, Sphera Funds Management opened a new position in State Street SPDR S&P Biotech ETF worth $32.5M.

  • Sphera Funds Management's largest Q2 2022 buy was State Street SPDR S&P Biotech ETF: 437,748 shares worth $32.5M.
  • Sphera Funds Management added most to Eli Lilly in Q2 2022, an estimated $18.6M increase.
  • Sphera Funds Management's biggest Q2 2022 reduction was Generac Holdings, cutting an estimated $9.81M.
  • Sphera Funds Management fully exited Pfizer in Q2 2022, selling an estimated $26.7M.
  • Sphera Funds Management's ten largest holdings make up 71% of its $935M portfolio in Q2 2022.
  • Sphera Funds Management opened 20 new positions and closed 29 in Q2 2022.
  • Sphera Funds Management's portfolio value rose 32% quarter-over-quarter to $935M.

Based on Sphera Funds Management's 13F filing for Q2 2022, filed 15 Aug 2022.